Brought to you by 
Jounce Therapeutics raises $56mm through Series B round
27 Jan 2017
Executive Summary
Jounce Therapeutics Inc. (cancer immunotherapies) raised $56mm in an oversubscribed Series B round by new investors Wellington Management, Redmile Group, Nextech Invest, Pharmstandard International SA (the venture investment division of Pharmstandard OJSC), Cormorant Asset Management, Omega Funds, Casdin Capital, Foresite Capital Management, and an undisclosed blue chip public investment fund.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Jounce Therapeutics raises $56mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice